does semaglutide decrease inflammation Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control Anti-inflammatory properties of GLP-1 receptor

While those claims have already been centralized in a federal GLP-1 stomach injury multidistrict litigation (MDL), a new series of lawsuits are emerging that point to a very different and potentially devastating side effect, sudden blindness

Hirsch says those symptoms are cause for concern

[PubMed]( 5

5- other GLP-1 trials in Parkinsons have been statistically negative or the results unclear, 6- the study was conducted in only very early Parkinsons cases, 7- the data, if replicable, may not be generalizable to all GLP-1 agonist drugs or to all subtypes of Parkinsons, and 8- the drug Lixisenatide requires a DAILY injection

The lawsuits are against drug manufacturers Novo Nordisk and Eli Lilly